Search Results

BioInvent International AB today announced that it will host a virtual KOL event on Tuesday, June 18, 2024 from 9:00-10:45 AM ET/3-4:45.

BioInvent International AB invites investors, analysts, and the press to a presentation of the year-end report 2023 at 2:00 pm on February 22.

BioInvent International AB today announced that the Annual Report for 2023 has been published.

BioInvent International AB announced that it will host a virtual KOL event on Tuesday, June 18, 2024 from 9:00-10:45 AM ET/3-4:45 PM CEST to discuss the recently presented clinical efficacy and safety data from its lead candidates BI-1808 and BI-1206, and TNFR2 and FcyRIIB as promising targets in immuno-oncology.

BioInvent International 2023 was a landmark year for BioInvent with positive clinical readouts from three Phase 1/2 programs.

BioInvent International AB announced a clinical supply agreement with AstraZeneca to evaluate BioInvent’s anti-FcyRIIB antibody, BI-1206, in combination with rituximab and Calquence®, in a Phase 1/2a study in non-Hodgkin’s lymphoma.

BioInvent International AB (“BioInvent”) (Nasdaq Stockholm:BINV) today announced that promising clinical data for BI-1206 in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), dosed in combination with rituximab, will be presented in a poster at the European Hematology Association congress held in Madrid, Spain from June 13-16, 2024.

BioInvent International AB announced that two abstracts for its two leading assets, BI-1808 and BI-1206, have been selected for presentation at ASCO 2024.